Uwe Trefzer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Uwe Trefzer has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
W. Sterry
5 shared publicationsM. Hofmann
4 shared publicationsF. Kiecker
Department of Dermatology and Allergy, Skin Cancer Center, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
3 shared publicationsWolfram Sterry
Department of Dermatology and Allergy, Skin Cancer Centre, Charité-Universitätsmedizin Berlin, Berlin, Germany
3 shared publications- Felix Kiecker
Department of Dermatology and Allergy, Skin Cancer Center, Charité Universitätsmedizin, Charitéplatz 1, 10117 Berlin, Germany
2 shared publications - Gunda Herberth
Department of Environmental Immunology, Helmholtz-Centre for Environmental Research - UFZ, Leipzig, Saxony, 04318, Germany
2 shared publications
Latest Publications
- 26 May 2011
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 43 (06) , 490-498
Algorithm for detection of small-bowel metastasis in malignant melanoma of the skin
Background and study aim: The aim of this study was to develop an algorithm to detect small-bowel metastasis (SBM) of melanoma by sequential laboratory parameters and pan-intestinal endoscopy (PIE) including video capsule endoscopy (VCE). Patients and methods: A total of 390 melanoma patients (AJCC stage I/II/III/IV, 140/80/121/49) were screened for signs of intestinal blood loss (fecal occult blood test [FOBT] or overt bleeding) in an open, multicenter, prospective study, and those who were positive underwent PIE. Independent of the presence of intestinal bleeding, all stage IV patients were offered PIE. Follow-up was obtained in 357 patients (91.5 %) for a median of 16 months. We undertook to identify possible associations between SBM and clinical and laboratory data. Survival data were analyzed with regard to clinical and laboratory data and small-bowel findings. Results: Intestinal blood loss was suspected in 49 of 390 patients (12.6 %), 38 of whom (77.6 %) agreed to undergo endoscopy. In 10 patients, SBM was detected by VCE (intention-to-diagnose, 20.4 %; AJCC III, n = 2; AJCC IV, n = 8). The SBM was resected in five patients. Total detection rates of SBM were 14 of 49 patients in stage IV (28.6 %, intention-to-diagnose), 2 of 121 in stage III (1.7 %), and 0 in stage I/II. In FOBT-positive patients, SBM detection rates were 72.7 %, 14.3 %, and 0 % in tumor stages IV, III, and I/II, respectively. Positive FOBT proved to be an independent negative prognostic factor for total survival in stage III and IV melanoma. Conclusions: SBMs are frequent in advanced melanoma. In stage III patients, screening for intestinal blood loss by PIE may help to identify SBMs. In stage IV, indication for PIE should depend on the individual consequences of detecting SBM, but not on bleeding symptoms alone.
- 26 May 2011
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 43 (06) , 490-498
Algorithm for detection of small-bowel metastasis in malignant melanoma of the skin
Background and study aim: The aim of this study was to develop an algorithm to detect small-bowel metastasis (SBM) of melanoma by sequential laboratory parameters and pan-intestinal endoscopy (PIE) including video capsule endoscopy (VCE). Patients and methods: A total of 390 melanoma patients (AJCC stage I/II/III/IV, 140/80/121/49) were screened for signs of intestinal blood loss (fecal occult blood test [FOBT] or overt bleeding) in an open, multicenter, prospective study, and those who were positive underwent PIE. Independent of the presence of intestinal bleeding, all stage IV patients were offered PIE. Follow-up was obtained in 357 patients (91.5 %) for a median of 16 months. We undertook to identify possible associations between SBM and clinical and laboratory data. Survival data were analyzed with regard to clinical and laboratory data and small-bowel findings. Results: Intestinal blood loss was suspected in 49 of 390 patients (12.6 %), 38 of whom (77.6 %) agreed to undergo endoscopy. In 10 patients, SBM was detected by VCE (intention-to-diagnose, 20.4 %; AJCC III, n = 2; AJCC IV, n = 8). The SBM was resected in five patients. Total detection rates of SBM were 14 of 49 patients in stage IV (28.6 %, intention-to-diagnose), 2 of 121 in stage III (1.7 %), and 0 in stage I/II. In FOBT-positive patients, SBM detection rates were 72.7 %, 14.3 %, and 0 % in tumor stages IV, III, and I/II, respectively. Positive FOBT proved to be an independent negative prognostic factor for total survival in stage III and IV melanoma. Conclusions: SBMs are frequent in advanced melanoma. In stage III patients, screening for intestinal blood loss by PIE may help to identify SBMs. In stage IV, indication for PIE should depend on the individual consequences of detecting SBM, but not on bleeding symptoms alone.
- 1 October 2009
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 34 (7) , e414-e415
Hypertrichosis in three patients treated with interferon-α2
- 1 October 2009
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 34 (7) , e414-e415
Hypertrichosis in three patients treated with interferon-α2
- 1 October 2008
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 6 (10) , 899
Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
- 1 October 2008
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 6 (10) , 899
Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
- 11 August 2006
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 44 (08) , P360
Antineoplastische Effekte von Taurolidin in Kombination mit Zytokinen auf das abdominal disseminierte maligne Melanom – in vitro, ex vivo und Mausmodell
Hintergrund: In fortgeschrittenen Stadien des malignen Melanoms finden sich oft Metastasen im Bauchraum, welche den Krankheitsverlauf erheblich beeinflussen. Therapie der Wahl sind Kombinationen aus Immun- und Chemotherapie-ohne Einfluss auf die ÜLZ. Deshalb werden neue therapeutische Ansätze gesucht. Taurolidin ist ein antineoplastisches Agens, das Apoptose induziert. Im Tierexperiment hemmt die nebenwirkungsarme Substanz Kolontumoren. In einer in-vitro und ex vivo Studie werden nun die Effekte der Kombination von Taurolidin mit melanomtoxischen Zytokinen untersucht. Folgend wurden in einem Mausmodell intraperitoneale und intravenöse Therapieoptionen geprüft. Methodik: in vivo: Humane MeWo und SK-MEL28 Melanomzellen sowie gewonnene Zelllinien von acht Patienten (ex vivo) wurden 24h und 48h mit Taurolidin (0,05 bis 2mM: MeWo und SK-MEL28; 0,05–1,5mM in Patientenzell-Linien) behandelt. Darüber hinaus wurde die Wirkung der Kombination von Taurolidin mit verschiedenen Zytokinen (IFNα, IFNγ, TNFα, IL-1α, IL-1β, TGFβ, und IL-6) in verschiedenen Konzentrationsbereichen analysiert. Der Verlauf wurde nach 12h, 24h und 48h durch FACS (Apoptoserate) analysiert. Im Mausexperiment (C57/BL6) wurden bei 80 Tieren Melanomzellen ip und am Rücken der Tiere injiziert. Nach 7 Tagen wurden 2 Gruppen randomisiert und mit 1%, 2% oder 3%Taurolidin ip (14 Therapien) oder iv (4 Therapien) behandelt. 28 Tage nach Tumorzellapplikation wurden die Tiere obduziert und das Gesamttumorgewicht bestimmt. Ergebnisse: in vitro: Nach 1mM Taurolidin und 24h in zeigte sich bei 55% MeWo und SK-MEL28 ein Zelltod, nach 48h 68%. ex vivo: Bei 1mM Taurolidintherapie wurde 100% Zelltod nachgewiesen. Der stärkste apoptotische Effekt trat nach 24h auf. Die Kombination mit Zytokinen hatte keinen apoptosesteigernden Effekt. Mausmodell: Eine ip-Therapie inhibiert abdominales Wachstum, eine iv-Therapie senkt Wachstum von Fernmetastasen schon bei geringen Dosen. Die Anzahl der Tumorimplantate korreliert mit der Dosis. Schlussfolgerung: Taurolidin induziert in vivo und ex vivo Apoptose. Im Mausmodell (disseminiertes Melanom) kann die Substanz intraperitoneales und subkutanes Tumorwachstum verzögern. In einer Phase III Studie wird die Sicherheit bei iv Applikation überprüft.
- 11 August 2006
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 44 (08) , P360
Antineoplastische Effekte von Taurolidin in Kombination mit Zytokinen auf das abdominal disseminierte maligne Melanom – in vitro, ex vivo und Mausmodell
Hintergrund: In fortgeschrittenen Stadien des malignen Melanoms finden sich oft Metastasen im Bauchraum, welche den Krankheitsverlauf erheblich beeinflussen. Therapie der Wahl sind Kombinationen aus Immun- und Chemotherapie-ohne Einfluss auf die ÜLZ. Deshalb werden neue therapeutische Ansätze gesucht. Taurolidin ist ein antineoplastisches Agens, das Apoptose induziert. Im Tierexperiment hemmt die nebenwirkungsarme Substanz Kolontumoren. In einer in-vitro und ex vivo Studie werden nun die Effekte der Kombination von Taurolidin mit melanomtoxischen Zytokinen untersucht. Folgend wurden in einem Mausmodell intraperitoneale und intravenöse Therapieoptionen geprüft. Methodik: in vivo: Humane MeWo und SK-MEL28 Melanomzellen sowie gewonnene Zelllinien von acht Patienten (ex vivo) wurden 24h und 48h mit Taurolidin (0,05 bis 2mM: MeWo und SK-MEL28; 0,05–1,5mM in Patientenzell-Linien) behandelt. Darüber hinaus wurde die Wirkung der Kombination von Taurolidin mit verschiedenen Zytokinen (IFNα, IFNγ, TNFα, IL-1α, IL-1β, TGFβ, und IL-6) in verschiedenen Konzentrationsbereichen analysiert. Der Verlauf wurde nach 12h, 24h und 48h durch FACS (Apoptoserate) analysiert. Im Mausexperiment (C57/BL6) wurden bei 80 Tieren Melanomzellen ip und am Rücken der Tiere injiziert. Nach 7 Tagen wurden 2 Gruppen randomisiert und mit 1%, 2% oder 3%Taurolidin ip (14 Therapien) oder iv (4 Therapien) behandelt. 28 Tage nach Tumorzellapplikation wurden die Tiere obduziert und das Gesamttumorgewicht bestimmt. Ergebnisse: in vitro: Nach 1mM Taurolidin und 24h in zeigte sich bei 55% MeWo und SK-MEL28 ein Zelltod, nach 48h 68%. ex vivo: Bei 1mM Taurolidintherapie wurde 100% Zelltod nachgewiesen. Der stärkste apoptotische Effekt trat nach 24h auf. Die Kombination mit Zytokinen hatte keinen apoptosesteigernden Effekt. Mausmodell: Eine ip-Therapie inhibiert abdominales Wachstum, eine iv-Therapie senkt Wachstum von Fernmetastasen schon bei geringen Dosen. Die Anzahl der Tumorimplantate korreliert mit der Dosis. Schlussfolgerung: Taurolidin induziert in vivo und ex vivo Apoptose. Im Mausmodell (disseminiertes Melanom) kann die Substanz intraperitoneales und subkutanes Tumorwachstum verzögern. In einer Phase III Studie wird die Sicherheit bei iv Applikation überprüft.
- 9 June 2006
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 20 (9) , 1135-1137
Vitiligo‐like depigmentation as a presenting sign of metastatic melanoma
- 9 June 2006
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 20 (9) , 1135-1137
Vitiligo‐like depigmentation as a presenting sign of metastatic melanoma
- 1 April 2006
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 16 (2) , 137-145
Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy
Because of its known heterogeneity, the analysis of antigen expression is crucial prior to the initiation of antigen-specific immunotherapy for melanoma. The melanoma differentiation antigens gp100, MART-1 and tyrosinase are involved in a common pathway of melanin synthesis. Peptides derived from these melanoma differentiation antigens are used in the immunotherapy of melanoma and antibodies recognizing these antigens are commonly applied to detect melanocytic lesions. One hundred and ninety-one paraffin-embedded melanoma metastases from 28 patients with 2–19 lesions (mean, 6.8) developing synchronously (n=67) or asynchronously (n=124) were analysed by immunohistochemistry for the expression of the melanoma differentiation antigens, as well as cancer/testis antigens of the melanoma antigen-A (MAGE-A) family (monoclonal antibodies 77B and 57B), anti-S100 and SM5-1. The overall reactivities were 81.6% (gp100), 79.5% (MART-1), 59.6% (tyrosinase), 59.1% (77B), 60.7% (57B), 93.2% (S100) and 91.6% (SM5-1). Twenty-seven lesions (14.1%) were positive for all tumour-associated antigens, 75 lesions (39.2%) were negative for one antigen and 87 lesions (45.5%) were negative for several tumour-associated antigens. Co-ordinated loss was found for lesions negative for gp100 and MART-1 (9.4%, PP=0.009), MART-1 and tyrosinase (15.2%, PP<0.0005), which is up to six times higher than the expected calculated loss. This co-ordinated loss of melanoma differentiation antigens in melanoma did not include cancer testis antigens and S100 or SM5-1. On average, the melanoma differentiation antigens stained 50–65% of cells within a lesion, and 10–39% of synchronous clusters were heterogeneous for melanoma differentiation antigen expression. In conclusion, broader polypeptide vaccines should be used for melanoma immunotherapy.
- 1 April 2006
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 16 (2) , 137-145
Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy
Because of its known heterogeneity, the analysis of antigen expression is crucial prior to the initiation of antigen-specific immunotherapy for melanoma. The melanoma differentiation antigens gp100, MART-1 and tyrosinase are involved in a common pathway of melanin synthesis. Peptides derived from these melanoma differentiation antigens are used in the immunotherapy of melanoma and antibodies recognizing these antigens are commonly applied to detect melanocytic lesions. One hundred and ninety-one paraffin-embedded melanoma metastases from 28 patients with 2–19 lesions (mean, 6.8) developing synchronously (n=67) or asynchronously (n=124) were analysed by immunohistochemistry for the expression of the melanoma differentiation antigens, as well as cancer/testis antigens of the melanoma antigen-A (MAGE-A) family (monoclonal antibodies 77B and 57B), anti-S100 and SM5-1. The overall reactivities were 81.6% (gp100), 79.5% (MART-1), 59.6% (tyrosinase), 59.1% (77B), 60.7% (57B), 93.2% (S100) and 91.6% (SM5-1). Twenty-seven lesions (14.1%) were positive for all tumour-associated antigens, 75 lesions (39.2%) were negative for one antigen and 87 lesions (45.5%) were negative for several tumour-associated antigens. Co-ordinated loss was found for lesions negative for gp100 and MART-1 (9.4%, PP=0.009), MART-1 and tyrosinase (15.2%, PP<0.0005), which is up to six times higher than the expected calculated loss. This co-ordinated loss of melanoma differentiation antigens in melanoma did not include cancer testis antigens and S100 or SM5-1. On average, the melanoma differentiation antigens stained 50–65% of cells within a lesion, and 10–39% of synchronous clusters were heterogeneous for melanoma differentiation antigen expression. In conclusion, broader polypeptide vaccines should be used for melanoma immunotherapy.
- Open Access
- 13 March 2006
- Published by Springer Nature in BMC Medicine
- Vol. 4 (1) , 5
HLA-B8 association with late-stage melanoma – an immunological lesson?
Background: Differences in HLA allele frequencies between the diseased and healthy populations may signify efficient immune responses, a notion that has been successfully tested for infectious diseases or for association with genetic elements involved in a distinct type of immunity. This retrospective study is intended to detect differences in MHC class I carrier frequencies of advanced melanoma patients compared to healthy bone marrow donors.Methods: The HLA-A and -B carrier frequencies of 748 stage IV melanoma patients retrieved from serotyping at 6 different centers in Germany were compared using a chi-square test to 13,386 fully HLA typed bone marrow donors registered in the German national bone marrow donor registry.Results: The comparison of HLA carrier frequencies in advanced cancer patients with healthy bone marrow donors revealed a significant decrease in HLA-B8 carrier frequencies, which was also apparent in patients with advanced disease compared to patients with loco-regional disease.Conclusion: The data suggest that protective immune responses restricted to distinct MHC class I molecules may be operational in a subset of melanoma patients, which is the prerequisite for a large scale screen for the corresponding epitopes. Alternatively, the known association of the ancestral haplotype HLA-A1, -B8 and -DR3 with genetic elements such as distinct TNF-α alleles might have a protective effect on disease progression. In any case, identification of the cause of protection within this patient subset might lead to a significant improvement in the efficacy of current immunotherapeutic approaches.
- 13 March 2006
- Published by Springer Nature in BMC Medicine
- Vol. 4 (1) , 5
Open AccessHLA-B8 association with late-stage melanoma – an immunological lesson?
Background: Differences in HLA allele frequencies between the diseased and healthy populations may signify efficient immune responses, a notion that has been successfully tested for infectious diseases or for association with genetic elements involved in a distinct type of immunity. This retrospective study is intended to detect differences in MHC class I carrier frequencies of advanced melanoma patients compared to healthy bone marrow donors.Methods: The HLA-A and -B carrier frequencies of 748 stage IV melanoma patients retrieved from serotyping at 6 different centers in Germany were compared using a chi-square test to 13,386 fully HLA typed bone marrow donors registered in the German national bone marrow donor registry.Results: The comparison of HLA carrier frequencies in advanced cancer patients with healthy bone marrow donors revealed a significant decrease in HLA-B8 carrier frequencies, which was also apparent in patients with advanced disease compared to patients with loco-regional disease.Conclusion: The data suggest that protective immune responses restricted to distinct MHC class I molecules may be operational in a subset of melanoma patients, which is the prerequisite for a large scale screen for the corresponding epitopes. Alternatively, the known association of the ancestral haplotype HLA-A1, -B8 and -DR3 with genetic elements such as distinct TNF-α alleles might have a protective effect on disease progression. In any case, identification of the cause of protection within this patient subset might lead to a significant improvement in the efficacy of current immunotherapeutic approaches.
- 1 March 2006
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 20 (3) , 346-347
Parathyroid hormone-related protein-induced hypercalcaemia in metastatic melanoma
- 1 March 2006
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 20 (3) , 346-347
Parathyroid hormone-related protein-induced hypercalcaemia in metastatic melanoma
- 23 February 2006
- Published by Wiley in International Journal of Dermatology
- Vol. 45 (8) , 984-985
Unmasking of mixed connective tissue disease by adjuvant IFN alpha therapy for melanoma
- 23 February 2006
- Published by Wiley in International Journal of Dermatology
- Vol. 45 (8) , 984-985
Unmasking of mixed connective tissue disease by adjuvant IFN alpha therapy for melanoma
- Open Access
- 11 January 2006
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 8
The monoclonal antibody SM5-1 recognizes a fibronectin variant which is widely expressed in melanoma
Background: Previously we have generated the monoclonal antibody SM5-1 by using a subtractive immunization protocol of human melanoma. This antibody exhibits a high sensitivity for primary melanomas of 99% (248/250 tested) and for metastatic melanoma of 96% (146/151 tested) in paraffin embedded sections. This reactivity is superior to the one obtained by HMB-45, anti-MelanA or anti-Tyrosinase and is comparable to anti-S100. However, as compared to anti-S100, the antibody SM5-1 is highly specific for melanocytic lesions since 40 different neoplasms were found to be negative for SM5-1 by immunohistochemistry. The antigen recognized by SM5-1 is unknown. Methods: In order to characterize the antigen recognized by mAb SM5-1, a cDNA library was constructed from the metastatic human melanoma cell line SMMUpos in the Uni-ZAP lambda phage and screened by mAb SM5-1. The cDNA clones identified by this approach were then sequenced and subsequently analyzed. Results: Sequence analysis of nine independent overlapping clones (length 3100–5600 bp) represent fibronectin cDNA including the ED-A, but not the ED-B region which are produced by alternative splicing. The 89aa splicing variant of the IIICS region was found in 8/9 clones and the 120aa splicing variant in 1/9 clones, both of which are included in the CS1 region of fibronectin being involved in melanoma cell adhesion and spreading. Conclusion: The molecule recognized by SM5-1 is a melanoma associated FN variant expressed by virtually all primary and metastatic melanomas and may play an important role in melanoma formation and progression. This antibody is therefore not only of value in immunohistochemistry, but potentially also for diagnostic imaging and immunotherapy.
- 11 January 2006
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 8
Open AccessThe monoclonal antibody SM5-1 recognizes a fibronectin variant which is widely expressed in melanoma
Background: Previously we have generated the monoclonal antibody SM5-1 by using a subtractive immunization protocol of human melanoma. This antibody exhibits a high sensitivity for primary melanomas of 99% (248/250 tested) and for metastatic melanoma of 96% (146/151 tested) in paraffin embedded sections. This reactivity is superior to the one obtained by HMB-45, anti-MelanA or anti-Tyrosinase and is comparable to anti-S100. However, as compared to anti-S100, the antibody SM5-1 is highly specific for melanocytic lesions since 40 different neoplasms were found to be negative for SM5-1 by immunohistochemistry. The antigen recognized by SM5-1 is unknown. Methods: In order to characterize the antigen recognized by mAb SM5-1, a cDNA library was constructed from the metastatic human melanoma cell line SMMUpos in the Uni-ZAP lambda phage and screened by mAb SM5-1. The cDNA clones identified by this approach were then sequenced and subsequently analyzed. Results: Sequence analysis of nine independent overlapping clones (length 3100–5600 bp) represent fibronectin cDNA including the ED-A, but not the ED-B region which are produced by alternative splicing. The 89aa splicing variant of the IIICS region was found in 8/9 clones and the 120aa splicing variant in 1/9 clones, both of which are included in the CS1 region of fibronectin being involved in melanoma cell adhesion and spreading. Conclusion: The molecule recognized by SM5-1 is a melanoma associated FN variant expressed by virtually all primary and metastatic melanomas and may play an important role in melanoma formation and progression. This antibody is therefore not only of value in immunohistochemistry, but potentially also for diagnostic imaging and immunotherapy.